Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 OMER | Healthcare | $17.49 | 737.38K | $1.30B | 9.16 | ― | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| OMER | Omeros | 17.49 | 9.62 | 122.24% |
| Name | Price | % Change | |
|---|---|---|---|
| OMER | $17.49 | +122.24% |
Omeros Corporation (OMER) is scheduled to report 3rd quarter earnings on 11/16/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Omeros Corporation to post earnings of $0.02
Omeros Corporation (OMER) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Omeros Corporation to post earnings of $0.02 per share. Revenue expectations
Omeros ( ($OMER) ) has shared an update. On October 28, 2026, Omeros’ board compensation committee granted CEO Gregory A. Demopulos a performance-based stock option for up to 500,000 shares,
H.C. Wainwright views the weakness in Omeros (OMER) shares following this morning’s negative Committee for Medicinal Products for Human Use opinion as overdone. The firm sees a buying opportunity ahead
The major averages were mixed near noon, with the Dow posting a small gain and the Nasdaq pulling back by 1%, as markets seek to stabilize at the end of
Omeros (OMER) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on the company’s marketing authorization application for narsoplimab for
Cantor Fitzgerald upgraded Omeros (OMER) to Overweight from Neutral with a $22 price target The left the company’s Q2 report with the belief that Yartemlea is having a much better
Cantor Fitzgerald analyst Olivia Brayer Saunders upgraded Omeros (OMER) to Overweight from Neutral with a $22 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking
Pre-earnings options volume in Omeros (OMER) is normal with calls leading puts 19:5. Implied volatility suggests the market is anticipating a move near 9.8%, or $1.32, after results are released.
Reports Q2 revenue $32.2M, consensus $12.67M. “We are very pleased with the strong momentum and growing market acceptance in the first full quarter of YARTEMLEA’s commercial launch,” said Gregory A.
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| OMER | Nov 16, 2026After Close | $1.30B | $0.02 | $37.28M | 3.32 | 9.16 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
